Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-002009
Filing Date
2020-02-12
Accepted
2020-02-12 06:16:38
Documents
42
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 288192
2 ex31-1.htm EX-31.1 15868
3 ex31-2.htm EX-31.2 15833
4 ex32-1.htm EX-32.1 5741
5 ex32-2.htm EX-32.2 5766
  Complete submission text file 0001493152-20-002009.txt   1834281

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE nxen-20191231.xml EX-101.INS 215537
7 XBRL SCHEMA FILE nxen-20191231.xsd EX-101.SCH 29087
8 XBRL CALCULATION FILE nxen-20191231_cal.xml EX-101.CAL 25871
9 XBRL DEFINITION FILE nxen-20191231_def.xml EX-101.DEF 97058
10 XBRL LABEL FILE nxen-20191231_lab.xml EX-101.LAB 200382
11 XBRL PRESENTATION FILE nxen-20191231_pre.xml EX-101.PRE 147255
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 20599640
SIC: 2834 Pharmaceutical Preparations